STOCK TITAN
  1. Home
  2. News
  3. RDHL

Redhill Biopharma Ltd. - RDHL STOCK NEWS

Welcome to our dedicated news page for Redhill Biopharma Ltd. (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharma Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Redhill Biopharma Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Redhill Biopharma Ltd.'s position in the market.

News
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) has announced that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued Nasdaq listing. The company maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, achieving compliance on December 8, 2023. This comes after previously receiving notification that the bid price for the American Depositary Shares (ADSs) had closed below the minimum $1.00 per share requirement for continued listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
-
News
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
Rhea-AI Summary
RedHill Biopharma Ltd. (RDHL) announces new non-dilutive external funding of approximately $4.8M to cover the RHB-107 arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. The Phase 2 RHB-107 arm has received FDA clearance to start and is estimated to be completed by the end of 2024. RHB-107 showed a 100% reduction in hospitalization due to COVID-19 in a U.S. Phase 2 study, with a 88% reduction in new severe COVID-19 symptoms and a faster recovery period. The study will compare investigational products to control in non-hospitalized adult SARS-CoV-2 infected participants with at least two moderate-severe symptoms at baseline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.86%
Tags
clinical trial covid-19
-
News
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
Rhea-AI Summary
RedHill Biopharma Ltd. (RDHL) has announced that the U.S. FDA has granted five years' market exclusivity for Talicia under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation, in addition to three years' exclusivity granted for the approval of Talicia under section 505(b)(2). Talicia is protected by its broad intellectual property suite to 2034. Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists for the eradication of H. pylori, a bacterial infection that affects approximately 35% of the U.S. adult population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
216.46%
Tags
none
News
RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market
Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) has received approval from Nasdaq to transfer the listing of the American Depositary Shares (ADSs) to the Nasdaq Capital Market. The transfer will take place on November 15, 2023, with trading unaffected and continuing under the same ticker symbol of 'RDHL.' The transfer follows a delisting notification due to non-compliance with the minimum Market Value of Publicly Held Shares (MVPHS) requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.03%
Tags
none
-
News
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
Rhea-AI Summary
RedHill Biopharma's oral opaganib shows statistically significant increase in survival time in a U.S. Army-funded Ebola virus study, making it the first host-directed molecule to show activity in Ebola virus disease. Opaganib has also demonstrated antiviral benefit in late-stage clinical studies of COVID-19 patients. Promising potential for treating infectious viral diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.86%
Tags
none
-
News
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Rhea-AI Summary
RedHill Biopharma received a letter from Nasdaq indicating that its bid price for ADSs closed below the minimum $1.00 per share requirement for continued listing. The company has 180 days to regain compliance. If not, it may be eligible for an additional 180-day period. RedHill also received a notification for not complying with the minimum market value of publicly held shares requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
RedHill Announces FDA sNDA Approval for Talicia®
Rhea-AI Summary
FDA approves sNDA for Talicia, changing dosing to a simplified TID regimen, improving patient adherence
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
-
News
RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)
Rhea-AI Summary
USPTO issues Notice of Allowance for new opaganib patent for Ebola treatment, providing protection until Oct 2035. European Patent Office grants new RHB-102 patent for nausea, vomiting, and diarrhea treatment, protection until Mar 2035.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
News
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
Rhea-AI Summary
RedHill Biopharma reports H1/23 Talicia net revenues of $5.1 million and cash balance of $16.3 million as of June 30, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.41%
Tags
earnings
News
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
Rhea-AI Summary
RedHill's partner, Gaelan Medical, has received marketing approval from the UAE Ministry of Health for Talicia, a rifabutin-containing all-in-one oral capsule to treat H. pylori. Talicia is the leading first-line therapy prescribed by U.S. gastroenterologists for H. pylori eradication. The approval makes Talicia the first rifabutin-containing combination product for H. pylori in the UAE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
Stock RDHL logo
Redhill Biopharma Ltd.

Nasdaq:RDHL

RDHL Rankings

#5297 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

RDHL Stock Data

13.56M
3.30B
6.25%
3.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
21 Haarbaa St

About RDHL

redhill biopharma is a biopharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs. redhill has an experienced management team, board of directors and advisory board based in israel, the us, canada and europe, with successful track record at big and small pharma of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise